Is The Superiority Of Entresto Just An Illusion?

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a mega-blockbuster. Some suggest $10 billion per annum peak sales may be achievable, making it one of the biggest selling drugs of all time.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news